advanced or recurrent esophageal or gastric carcinoma
Conditions
Interventions
aprepitant
palonosetron
Sponsors
Kitasato University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patient with advanced or recurrent esophageal or gastric carcinoma 2. Chemotherapy including cisplatin 60 mg/m2 or more is planned 3. Chemotherapy-naive patient 4. Two courses or more of chemotherapy is planned
Exclusion criteria
Exclusion criteria: 1. Serious heart disease, serious renal disease, serious liver disease, and poor controlled Diabetes 2. Woman during the pregnancy or with the possibility of the pregnancy 3. Patient with severe mental disorder 4. The allergic past history for the serotonin receptor antagonist 5. Patient with nausea, vomiting due to brain tumor or ileus 6. Patient who plans to receive radiotherapy for the chest, abdomen, or pelvis 7. Patient using antiemetic drug within 48 hours before chemotherapy 8.Patients who are judged inappropriate for the entry into this study by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete response (no emesis and no rescue therapy) within 120 hours after the start of the first course of chemotherapy | — |
Countries
Japan
Contacts
Public ContactKenji Ishido
Kitasato University School of Medicine Department of Gastroenterology
Outcome results
None listed